SCYNEXIS (SCYX) Insider Guy Macdonald Buys 2,875 Shares

Guy Macdonald recently purchased 2,875 shares of SCYNEXIS, Inc. (NasdaqCM: SCYX) on June 26, 2026. The transaction was not planned under a Rule 10b5-1 trading plan. Shares of SCYNEXIS were trading at $4.07 on Wednesday.

Insider Buying and Selling at SCYNEXIS, Inc.

On June 26, 2026, several insiders, including Guy Macdonald, bought 2,875 shares each of SCYNEXIS, Inc. These transactions were not made under a pre-planned trading program. Other insiders making similar purchases on the same day include Armando Anido, Ann Hanham, Brian Philippe Tinmouth, and David Hastings.

Other Institutional Activity in SCYNEXIS, Inc.

Several institutional investors have also shown interest in SCYNEXIS, Inc. Squadron Capital Management LLC opened a new position with 7,608,695 shares valued at approximately $6.98 million. Similarly, Heights Capital Management, Inc. initiated a stake with 2,086,960 shares worth about $1.91 million. Avidity Partners Management LP maintained its position with 2,081,660 shares valued at $1.91 million. Kingdon Capital Management, L.L.C. and Empery Asset Management, LP also opened new positions with 1,982,491 and 1,847,826 shares, respectively.

SCYNEXIS, Inc. Stock Down 8.7%

Shares of SCYNEXIS, Inc. traded near $4.07 on Wednesday. The company has a market cap of approximately $40.4 million and a beta of 1.063. Over the past 52 weeks, the stock has ranged from $3.68 to $10.48. The 50-day moving average is $5.88, while the 200-day moving average stands at $6.13. SCYNEXIS maintains a current ratio of 3.943 and a quick ratio of 3.727, with a debt-to-equity ratio of 4.989.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on SCYNEXIS, Inc. On October 28, 2025, Guggenheim maintained a 'buy' rating with a price target of $3.00. Ladenburg Thalmann & Co. also maintained a 'buy' rating with a target of $7.50 on May 10, 2024. Overall, the consensus among analysts is favorable, with a mean price target of $33.55 based on three opinions.

About SCYNEXIS, Inc.

SCYNEXIS, Inc. is a biotechnology company based in Jersey City, New Jersey. It focuses on developing treatments for difficult-to-treat and drug-resistant fungal infections. The company markets BREXAFEMME for vulvovaginal candidiasis and is developing SCY-247 for invasive fungal infections, currently in Phase I clinical trials. Led by CEO Dr. David Gonzalez Angulo, SCYNEXIS employs around 18 people.

Bottom Line

Guy Macdonald's recent purchase of SCYNEXIS shares reflects ongoing interest in the company from insiders. Institutional investors are also opening new positions, suggesting confidence in the company's future. However, investors should remember that insider and institutional trades are historical data and may not indicate current positions.